Skip to main content

Table 1 Baseline characteristics of study patients

From: Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique

Characteristic Total (n = 297) Nevirapine plasma conc. ≥3.0 mg/L (n = 282) Nevirapine plasma conc. <3.0 mg/L (n = 15)
Sex, female 201 (67.7) 192 (68.1) 9 (60.0)
Age (years) 39.1 (32.8-45.2) 39.2 (33.1-45.2) 33.3 (30.9-42.8)
Time on ART (months) 28.5 (25.8-33.5) 28.1 (25.9-32.6) 31.1 (24.4-41.2)
NRTI backbone    
  zidovudine 235 (79.1) 223 (79.1) 12 (80.0)
  tenofovir 19 (6.4) 17 (6.0) 2 (13.3)
HIV-RNA >400 copies/mL* 21 (8.9) 18 (8.1) 3 (23.1)
30-day adherence    
  100% 260 (91.6) 248 (91.9) 12 (85.7)
  95- < 100% 19 (6.7) 18 (6.7) 1 (7.1)
  <95% 5 (1.8) 4 (1.5) 1 (7.1)
3-day adherence (any pills missed) 9 (3.3) 6 (2.3) 3 (20.0)
CD4 cell count (cells/mm3) 363 (265–509) 385 (269.5-511) 299 (211–354)
  1. Baseline characteristics stratified by patients with therapeutic (≥3.0 mg/l) or subtherapeutic (<3.0 mg/L) nevirapine plasma concentrations.
  2. Values in brackets are n (%) for categorical variables and median (interquartile range, IQR) for continuous variables. * HIV-RNA results from 235 patients were available.